Literature DB >> 14638881

A population based epidemiological study on myasthenia gravis in Estonia.

M Oöpik1, A-E Kaasik, J Jakobsen.   

Abstract

OBJECTIVE: To describe the occurrence of myasthenia gravis in the Baltic area.
METHODS: Data were obtained from hospital files recorded during the period 1942 to 1996 from neurologists and the patient organisation. Survival data were checked with the Estonian Citizenship and Migration Board. Prevalence was determined on 1 January 1997. A questionnaire on the course of myasthenia gravis was sent to all the prevalent patients.
RESULTS: The size of the population surveyed was 1 462 130. The average annual incidence from 1970 to 1996 was 4.0 per million (women, 5.2; men, 2.6). The point prevalence was 99 per million (women, 133; men 59). The incidence in the younger age group (<50 years) was 3.4 per million (women, 4.8; men, 1.9) and in the older age group (>or=50 years), 5.5 (women, 5.9; men, 4.9). The prevalence ratio was twofold higher in the older age group (p<0.0001)-for men (p = 0.034) as well as for women (p<0.001).
CONCLUSIONS: Prevalence and incidence values of myasthenia gravis from Estonia are similar to those reported in most studies from Europe and north America. However, there seems to be a higher frequency in the elderly (>or=50 years) in Estonia.

Entities:  

Mesh:

Year:  2003        PMID: 14638881      PMCID: PMC1757432          DOI: 10.1136/jnnp.74.12.1638

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  27 in total

1.  The epidemiology of myasthenia gravis in central and western Virginia.

Authors:  L H Phillips; J C Torner; M S Anderson; G M Cox
Journal:  Neurology       Date:  1992-10       Impact factor: 9.910

2.  Epidemiologic evidence for a changing natural history of myasthenia gravis.

Authors:  L H Phillips; J C Torner
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

3.  The prevalence of some neurological diseases in Iceland.

Authors:  K R Gudmundsson
Journal:  Acta Neurol Scand       Date:  1968       Impact factor: 3.209

4.  Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983-1992).

Authors:  D Lavrnić; M Jarebinski; V Rakocević-Stojanović; Z Stević; S Lavrnić; S Pavlović; R Trikić; I Tripković; V Nesković; S Apostolski
Journal:  Acta Neurol Scand       Date:  1999-09       Impact factor: 3.209

5.  Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.

Authors:  R Beekman; J B Kuks; H J Oosterhuis
Journal:  J Neurol       Date:  1997-02       Impact factor: 4.849

6.  Genetic aspects in myasthenia gravis. A family study of 264 Finnish patients.

Authors:  R Pirskanen
Journal:  Acta Neurol Scand       Date:  1977-11       Impact factor: 3.209

7.  Incidence and prevalence of myasthenia gravis in the county of the coast and Gorski kotar, Croatia, 1976 through 1996.

Authors:  R Zivadinov; A Jurjevic; K Willheim; G Cazzato; M Zorzon
Journal:  Neuroepidemiology       Date:  1998       Impact factor: 3.282

8.  Epidemiology of myasthenia gravis in Norway.

Authors:  A Storm-Mathisen
Journal:  Acta Neurol Scand       Date:  1984-10       Impact factor: 3.209

9.  Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey.

Authors:  F E Somnier; N Keiding; O B Paulson
Journal:  Arch Neurol       Date:  1991-07

10.  Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989.

Authors:  P B Christensen; T S Jensen; I Tsiropoulos; T Sørensen; M Kjaer; E Højer-Pedersen; M J Rasmussen; E Lehfeldt; B de Fine Olivarius
Journal:  Neurology       Date:  1993-09       Impact factor: 9.910

View more
  9 in total

1.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

2.  Estimation of incidence, prevalence, and age-at-diagnosis of myasthenia gravis among adults by hospital discharge records.

Authors:  Anett Foldvari; Nora Kovacs; Valeria Sipos; Gabriella Merth; Ferenc Vincze; Maria Szucs; Janos Sandor
Journal:  Wien Klin Wochenschr       Date:  2015-05-20       Impact factor: 1.704

Review 3.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

Review 4.  Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases.

Authors:  Glinda S Cooper; Milele L K Bynum; Emily C Somers
Journal:  J Autoimmun       Date:  2009-10-09       Impact factor: 7.094

5.  Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity.

Authors:  Claudia Sardu; Eleonora Cocco; Alessandra Mereu; Roberta Massa; Alessandro Cuccu; Maria Giovanna Marrosu; Paolo Contu
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

6.  Prevalence of factors associated with poor outcomes of hospitalized myasthenia gravis patients in Thailand.

Authors:  Somsak Tiamkao; Sineenard Pranboon; Kaewjai Thepsuthammarat; Kittisak Sawanyawisuth
Journal:  Neurosciences (Riyadh)       Date:  2014-10       Impact factor: 0.906

7.  Diversity in mental fatigue and social profile of patients with myasthenia gravis in two different Northern European countries.

Authors:  Liis Sabre; Elisabet Westerberg; Maarika Liik; Anna R Punga
Journal:  Brain Behav       Date:  2017-03-01       Impact factor: 2.708

8.  Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.

Authors:  Nader Salari; Behnaz Fatahi; Yalda Bartina; Mohsen Kazeminia; Reza Fatahian; Payam Mohammadi; Shamarina Shohaimi; Masoud Mohammadi
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

9.  The Epidemiology of Myasthenia Gravis in Korea.

Authors:  Hyung Seok Lee; Hye Sun Lee; Ha Young Shin; Young Chul Choi; Seung Min Kim
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.